4 most recent filings and news items mentioning BLFS. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/BLFS/news?limit=20"
Pull BLFS filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayBioLife reported a 21% increase in Q2 2026 revenue to $28.5 million. Additionally, the company announced that Repligen will acquire BioLife for approximately $1.5 billion, with the deal expected to close in Q4 2026.
View filing at SEC.gov →Repligen CEO Olivier Loeillot highlights Bio-Life's industry leadership and outlines the integration of their cell processing operations, targeting a fourth-quarter closing.
View filing at SEC.gov →Biolife Solutions announced a definitive agreement to acquire Repligen Corp in a cash and stock transaction valued at approximately $3.55 billion. This strategic M&A deal expands Biolife's capabilities in cell and gene therapy manufacturing.
View filing at SEC.gov →BioLife Solutions released a June 2026 investor presentation outlining its industry-leading solutions for cell-based therapies. The presentation includes financial metrics, non-GAAP measures, and forward-looking statements regarding company operations and market positioning.
View filing at SEC.gov →